Skip to Content
Morningstar

VanEck Pharmaceutical ETF PPH

Morningstar Medalist Rating
Medalist Rating as of | See VanEck Investment Hub

Morningstar’s Analysis PPH

Will PPH outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

  • Process Pillar

    The Process Pillar is our assessment of how sensible, clearly defined, and repeatable PPH’s performance objective and investment process is for both security selection and portfolio construction.

  • People Pillar

    The People Pillar is our evaluation of the PPH management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.

  • Parent Pillar

    The Parent Pillar is our rating of PPH’s parent organization’s priorities and whether they’re in line with investors’ interests.

VanEck Pharmaceutical ETF’s management team is rated Average, but a solid investment process still helps this strategy retain its Morningstar Medalist Rating of Bronze.

null Morningstar Manager Research

Morningstar Manager Research

Summary

The portfolio maintains a sizable cost advantage over competitors, priced within the least expensive fee quintile among peers.

by Morningstar Manager Research
Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings PPH

More PPH Holdings
  • Current Portfolio Date
  • Equity Holdings —
  • Bond Holdings —
  • Other Holdings —
  • % Assets in Top 10 Holdings 64.7
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Eli Lilly and Co

11.67 57.1 Mil
Healthcare

Novo Nordisk A/S ADR

9.57 46.8 Mil
Healthcare

Johnson & Johnson

6.63 32.4 Mil
Healthcare

Merck & Co Inc

6.31 30.9 Mil
Healthcare

AbbVie Inc

5.89 28.8 Mil
Healthcare

AstraZeneca PLC ADR

5.52 27.0 Mil
Healthcare

Novartis AG ADR

4.88 23.9 Mil
Healthcare

Cencora Inc

4.82 23.6 Mil
Healthcare

McKesson Corp

4.73 23.1 Mil
Healthcare

Haleon PLC ADR

4.67 22.8 Mil
Healthcare